Connection

Paola Rogliani to Pulmonary Disease, Chronic Obstructive

Back to Details
This is a "connection" page, showing publications Paola Rogliani has written about Pulmonary Disease, Chronic Obstructive.
Paola Rogliani
Connection Strength
4.384
Pulmonary Disease, Chronic Obstructive
  1. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids? Expert Rev Respir Med. 2021 04; 15(4):561-568.
    View in: PubMed
    Score: 0.250
  2. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019 04; 20(6):737-750.
    View in: PubMed
    Score: 0.220
  3. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018; 13:3115-3130.
    View in: PubMed
    Score: 0.215
  4. Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ Evid Based Med. 2018 10; 23(5):183-184.
    View in: PubMed
    Score: 0.211
  5. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018 06; 17(6):589-596.
    View in: PubMed
    Score: 0.210
  6. Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link? COPD. 2018 06; 15(3):310-311.
    View in: PubMed
    Score: 0.209
  7. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018 06; 50:28-37.
    View in: PubMed
    Score: 0.208
  8. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. Curr Opin Pharmacol. 2018 06; 40:34-38.
    View in: PubMed
    Score: 0.206
  9. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulm Pharmacol Ther. 2018 04; 49:20-26.
    View in: PubMed
    Score: 0.204
  10. Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 02; 12(2):103-112.
    View in: PubMed
    Score: 0.204
  11. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J Comp Eff Res. 2017 Oct; 6(7):627-636.
    View in: PubMed
    Score: 0.199
  12. Adherence to COPD treatment: Myth and reality. Respir Med. 2017 08; 129:117-123.
    View in: PubMed
    Score: 0.197
  13. Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulm Pharmacol Ther. 2017 08; 45:148-158.
    View in: PubMed
    Score: 0.197
  14. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017 03; 124:6-14.
    View in: PubMed
    Score: 0.192
  15. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J. 2011 Sep; 20(3):291-8.
    View in: PubMed
    Score: 0.132
  16. Management of COPD patients during COVID: difficulties and experiences. Expert Rev Respir Med. 2021 08; 15(8):1025-1033.
    View in: PubMed
    Score: 0.065
  17. Guidance on nebulization during the current COVID-19 pandemic. Respir Med. 2021 01; 176:106236.
    View in: PubMed
    Score: 0.062
  18. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Oct; 28(10):827-833.
    View in: PubMed
    Score: 0.057
  19. Pharmacological treatment and current controversies in COPD. F1000Res. 2019; 8.
    View in: PubMed
    Score: 0.057
  20. Disease awareness in patients with COPD: measurement and extent. Int J Chron Obstruct Pulmon Dis. 2019; 14:1-11.
    View in: PubMed
    Score: 0.055
  21. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0.055
  22. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018 Oct; 14(10):1101-1111.
    View in: PubMed
    Score: 0.054
  23. LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. Respiration. 2018; 96(4):370-381.
    View in: PubMed
    Score: 0.054
  24. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 08; 12(8):693-708.
    View in: PubMed
    Score: 0.053
  25. Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? Expert Opin Investig Drugs. 2018 07; 27(7):573-581.
    View in: PubMed
    Score: 0.053
  26. Impact of doxofylline in COPD: A pairwise meta-analysis. Pulm Pharmacol Ther. 2018 08; 51:1-9.
    View in: PubMed
    Score: 0.052
  27. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018 Jul; 103:1-8.
    View in: PubMed
    Score: 0.052
  28. Is ICS-LAMA an alternative option to treat patients with COPD? Lancet Respir Med. 2018 05; 6(5):316-317.
    View in: PubMed
    Score: 0.052
  29. Long-term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. Pol Arch Intern Med. 2018 01 31; 128(1):4-6.
    View in: PubMed
    Score: 0.051
  30. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulm Pharmacol Ther. 2018 02; 48:185-194.
    View in: PubMed
    Score: 0.051
  31. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. COPD. 2017 Dec; 14(6):641-647.
    View in: PubMed
    Score: 0.051
  32. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Rev Respir Med. 2018 01; 12(1):43-54.
    View in: PubMed
    Score: 0.051
  33. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis. 2017; 12:2687-2693.
    View in: PubMed
    Score: 0.050
  34. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids. Evid Based Med. 2017 10; 22(5):183-184.
    View in: PubMed
    Score: 0.050
  35. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends Pharmacol Sci. 2017 10; 38(10):940-951.
    View in: PubMed
    Score: 0.050
  36. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.
    View in: PubMed
    Score: 0.050
  37. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respir Med. 2017 08; 129:189-198.
    View in: PubMed
    Score: 0.049
  38. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs. 2017 May; 77(7):721-732.
    View in: PubMed
    Score: 0.049
  39. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017 01 24; 18(1):26.
    View in: PubMed
    Score: 0.048
  40. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan; 26(143).
    View in: PubMed
    Score: 0.048
  41. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opin Drug Saf. 2018 05; 17(5):509-517.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.